Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (1RO1NS094522-01, 1RO1NS113969-01)
Received: 11 March 2020
Accepted: 24 April 2020
First Online: 4 May 2020
Ethics approval and consent to participate
: The experiments were approved by the Institutional Animal Care and Use Committee at the University of Miami (IACUC protocol number: 17-086).
: Not applicable
: JPdRV, RWK, WDD, and HMB are co-founders and managing members of InflamaCORE, LLC and have licensed patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. JPdRV, RWK, WDD, and HMB are Scientific Advisory Board Members of ZyVersa Therapeutics, Inc. RB has licensed a patent on inflammasome proteins as a therapy for MS. All other authors declare that there are no conflicts of interest.